These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32678518)

  • 1. Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor.
    Smith H; Rayment JH
    Pediatr Pulmonol; 2020 Oct; 55(10):2493-2494. PubMed ID: 32678518
    [No Abstract]   [Full Text] [Related]  

  • 2. Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use.
    Megalaa R; Gopalareddy V; Champion E; Goralski JL
    Pediatr Pulmonol; 2019 Aug; 54(8):E16-E18. PubMed ID: 31066218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
    Munce D; Lim M; Akong K
    Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
    Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
    Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
    J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
    [No Abstract]   [Full Text] [Related]  

  • 8. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
    Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC;
    Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor.
    Nichols AL; Davies JC; Jones D; Carr SB
    Paediatr Respir Rev; 2020 Sep; 35():99-102. PubMed ID: 32386958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 14. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.
    Stallings VA; Sainath N; Oberle M; Bertolaso C; Schall JI
    J Pediatr; 2018 Oct; 201():229-237.e4. PubMed ID: 30029855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
    McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
    Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.